logo-loader
AIM:SNG OTC:SYGGF

Synairgen PLC

Receive alerts
Market:
AIM
Price
5.50 GBX
Day Change
-1.08%
Market Cap:
£11.07 m
52 weeks high
17.50
52 weeks low
4.50

In brief

Synairgen PLC is a UK-based respiratory company focused on drug discovery, development and commercialisation.

The company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs.

SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA).

Synairgen was founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003.

Snapshot

  • Synairgen appoints new CFO as incumbent bows out after nearly 20 years
  • Demand for healthcare stocks similar to late 90s tech boom, says analyst
  • Synairgen reaffirms dedication to key asset, says broker
  • Synairgen looking beyond COVID in fight against respiratory illness